Matching genes with constitution and environment

Sam Schulman

doi:10.1160/TH16-08-0634

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2016; 116(04): 592-594
DOI: 10.1160/TH16-08-0634

Invited Editorial Focus

Schattauer GmbH

Matching genes with constitution and environment

Authors

Sam Schulman

¹Department of Medicine, McMaster University and Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada

Abstract

Full Text

References

References
1 Rosendaal FR.. Venous thrombosis: a multicausal disease. Lancet 1999; 353: 1167-1173.
2 Egeberg O.. Inherited antithrombin III deficiency causing thrombophilia. Thromb Diath Haemorh 1965; 13: 515-530.
3 Bucciarelli P, Rosendaal FR, Tripodi A. et al. Risk of venous thromboembolism and clinical manifestations in carriers of antithrombin, protein C, protein S deficiency, or activated protein C resistance: a multicenter collaborative family study. Arterioscler Thromb Vasc Biol 1999; 19: 1026-1033.
4 De Stefano V, Leone G, Mastrangelo S. et al Thrombosis during pregnancy and surgery in patients with congenital deficiency of antithrombin III, protein C, protein S. Thromb Haemost 1994; 71: 799-800.
5 Conard J, Horellou MH, Van Dreden P. et al. Thrombosis and pregnancy in congenital deficiencies in AT III, protein C or protein S: study of 78 women. Thromb Haemost 1990; 63: 319-320.
6 van Boven HH, Vandenbroucke JP, Westendorp RG. et al Mortality and causes of death in inherited antithrombin deficiency. Thromb Haemost 1997; 77: 452-455.
7 Martinelli I, Mannucci PM, De Stefano V. et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood 1998; 92: 2353-2358.
8 Griffin JH, Evatt B, Zimmerman TS. et al. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981; 68: 1370-1373.
9 Comp PC, Nixon RR, Cooper MR. et al. Familial protein S deficiency is associated with recurrent thrombosis. J Clin Invest 1984; 74: 2082-2088.
10 Schwarz HP, Fischer M, Hopmeier P. et al. Plasma protein S deficiency in familial thrombotic disease. Blood 1984; 64: 1297-1300.
11 Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a co-factor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-1008.
12 Bertina RM, Koeleman BP, Koster T. et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
13 Poort SR, Rosendaal FR, Reitsma PH. et al. A common genetic variation in the 3’-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-3703.
14 Tang W, Teichert M, Chasman DI. et al. A genome-wide association study for venous thromboembolism: the extended cohorts for heart and aging research in genomic epidemiology (CHARGE) consortium. Genet Epidemiol 2013; 37: 512-521.
15 Bruzelius M, Bottai M, Sabater-Lleal M. et al. Predicting venous thrombosis in women using a combination of genetic markers and clinical risk factors. J Thromb Haemost 2015; 13: 219-227.
16 Sabater-Lleal M, Martinez-Perez A, Buil A. et al A genome-wide association study identifies KNG1 as a genetic determinant of plasma factor XI Level and activated partial thromboplastin time. Arterioscler Thromb Vasc Biol 2012; 32: 2008-2016.
17 Uitte de Willige S, de Visser MC, Houwing-Duistermaat JJ. et al Genetic variation in the fibrinogen gamma gene increases the risk for deep venous thrombosis by reducing plasma fibrinogen gamma’ levels. Blood 2005; 106: 4176-4183.
18 Heit JA, Armasu SM, Asmann YW. et al. A genome-wide association study of venous thromboembolism identifies risk variants in chromosomes 1q24.2 and 9q. J Thromb Haemost 2012; 10: 1521-1531.
19 Vasan SK, Rostgaard K, Majeed A. et al. ABO blood group and risk of thromboembolic and arterial disease: a study of 1.5 million blood donors. Circulation 2016; 133: 1449-1457.
20 Dentali F, Sironi AP, Ageno W. et al. Non-O blood type is the commonest genetic risk factor for VTE: results from a meta-analysis of the literature. Semin Thromb Hemost 2012; 38: 535-548.
21 Germain M, Chasman DI, de Haan H. et al. Meta-analysis of 65,734 individuals identifies TSPAN15 and SLC44A2 as two susceptibility loci for venous thromboembolism. Am J Hum Genet 2015; 96: 532-542.
22 Heit JA, Phelps MA, Ward SA. et al. Familial segregation of venous thromboembolism. J Thromb Haemost 2004; 02: 731-736.
23 Lutsey PL, Cushman M, Heckbert SR. et al. Longer legs are associated with greater risk of incident venous thromboembolism independent of total body height. The Longitudinal Study of Thromboembolism Etiology (LITE). Thromb Haemost 2011; 106: 113-120.
24 Enga KF, Braekkan SK, Hansen-Krone IJ. et al. Emotional states and future risk of venous thromboembolism: the Tromso Study. Thromb Haemost 2012; 107: 485-493.
25 Lippi G, Mattiuzzi C, Franchini M.. Sleep apnea and venous thromboembolism. A systematic review. Thromb Haemost 2015; 114: 958-963.
26 Alonso-Fernandez A, Garcia Suquia A, de la Pena M. et al Obstructive sleep apnea is a risk factor for recurrent venous thromboembolism. Chest. 2016 Epub ahead of print
27 Glynn RJ, Danielson E, Fonseca FA. et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009; 360: 1851-1861.
28 Desai CS, Martin SS, Blumenthal RS.. Non-cardiovascular effects associated with statins. Br Med J 2014; 349: g3743.
29 Bloemenkamp KW, Rosendaal FR, Helmerhorst FM. et al. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995; 346: 1593-1596.
30 Martinelli I, Sacchi E, Landi G. et al. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med 1998; 338: 1793-1797.
31 Legnani C, Cini M, Cosmi B. et al. Risk of deep vein thrombosis: interaction between oral contraceptives and high factor VIII levels. Haematologica 2004; 89: 1347-1351.
32 Caprini JA, Arcelus JI, Hasty JH. et al. Clinical assessment of venous thromboembolic risk in surgical patients. Semin Thromb Hemost 1991; 17: 304-312.
33 Rogers Jr. SO, Kilaru RK, Hosokawa P. et al. Multivariable predictors of postoperative venous thromboembolic events after general and vascular surgery: results from the patient safety in surgery study. J Am Coll Surg 2007; 204: 1211-1221.
34 Khorana AA, Kuderer NM, Culakova E. et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111: 4902-4907.
35 Barbar S, Noventa F, Rossetto V. et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost 2010; 08: 2450-2457.
36 Mahan CE, Liu Y, Turpie AG. et al. External validation of a risk assessment model for venous thromboembolism in the hospitalised acutely-ill medical patient (VTE-VALOURR). Thromb Haemost 2014; 112: 692-699.
37 de Haan HG, Bezemer ID, Doggen CJ. et al Multiple SNP testing improves risk prediction of first venous thrombosis. Blood 2012; 120: 656-663.
38 Soria JM, Morange PE, Vila J. et al. Multilocus genetic risk scores for venous thromboembolism risk assessment. J Am Heart Assoc 2014; 03: e001060.
39 Crous-Bou M, de Vivo I, Camargo Jr. CA. et al Interactions of established risk factors and a GWAS-based genetic risk score on the risk of venous thromboembolism. Thromb Haemost 2016; 116: 705-713.